a 4inch big blister was formed below injection site which is called Bulla; Onset of Migraine; Onset redness belowvaccination site; Onset of mild burning/ache at site of redness. NO itching.; Possible hyper cutaneous sensitivity.; This spontaneous case was reported by a consumer and describes the occurrence of DERMATITIS ALLERGIC (Possible hyper cutaneous sensitivity.), BLISTER (a 4inch big blister was formed below injection site which is called Bulla), MIGRAINE (Onset of Migraine), VACCINATION SITE ERYTHEMA (Onset redness belowvaccination site) and VACCINATION SITE PAIN (Onset of mild burning/ache at site of redness. NO itching.) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     The patient's past medical history included Cholecystectomy in 1994 and Hysterectomy in 1989. Family history included Oculopharyngeal dystrophy. Concurrent medical conditions included Restless leg syndrome since 2000, Migraine headache since 2001, Osteopenia, Hypothyroidism, Asthma, Iron metabolism disorder, Hypotension, Drug allergy (Allergy to sulfa), Drug allergy (Allergy to Tramadol) and Seasonal allergy. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHYROID) for Hypothyroidism, LAMOTRIGINE for Restless leg syndrome.    On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, the patient experienced DERMATITIS ALLERGIC (Possible hyper cutaneous sensitivity.), MIGRAINE (Onset of Migraine), VACCINATION SITE ERYTHEMA (Onset redness belowvaccination site) and VACCINATION SITE PAIN (Onset of mild burning/ache at site of redness. NO itching.). On 14-Feb-2021, the patient experienced BLISTER (a 4inch big blister was formed below injection site which is called Bulla). The patient was treated with PREDNISONE on 14-Feb-2021 for Adverse event, at a dose of 40 mg once a day; CEPHALEXIN [CEFALEXIN] 14-Feb-2021 for Adverse event, at a dose of 500 mg once a day; CAFFEINE, ERGOTAMINE TARTRATE, METAMIZOLE SODIUM (MIGRANOL [CAFFEINE;ERGOTAMINE TARTRATE;METAMIZOLE SODIUM]) on 13-Feb-2021 for Migraine, at an unspecified dose and frequency; CLOCORTOLONE PIVALATE (topical) on 16-Feb-2021 for Blister, at a dose of 1 dosage form twice a day; PARACETAMOL (TYLENOL) for Pain, at a dose of 1000 mg as required and IBUPROFEN (MOTRIN [IBUPROFEN]) for Pain, at a dose of 800 mg as required. On 14-Feb-2021, MIGRAINE (Onset of Migraine) had resolved. On 19-Feb-2021, BLISTER (a 4inch big blister was formed below injection site which is called Bulla) and VACCINATION SITE PAIN (Onset of mild burning/ache at site of redness. NO itching.) had resolved. On 06-Mar-2021, DERMATITIS ALLERGIC (Possible hyper cutaneous sensitivity.) had resolved. At the time of the report, VACCINATION SITE ERYTHEMA (Onset redness belowvaccination site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Patient demographics added. Medical history added. Concomitant drugs added. Treatment drugs added. Events added (Migraine, vaccination site pain, vaccination site erythema). Outcome updated.